Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.109 - matriptase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Matriptase activation, an early cellular response to acidosis.
Adenocarcinoma
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front.
Targeted HAI-2 deletion causes excessive proteolysis with prolonged active prostasin and depletion of HAI-1 monomer in intestinal but not epidermal epithelial cells.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Adenocarcinoma, Mucinous
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Adenoma
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Anemia
A critical role for murine transferrin receptor 2 in erythropoiesis during iron restriction.
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
A novel mutation Gly603Arg of TMPRSS6 in a Korean female with iron-refractory iron deficiency anemia.
A Novel mutation in the CUB sequence of matriptase-2 (Tmprss6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia - response to Jaspers et al.
A novel splice site mutation c.2278 (-1) G>C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia.
A novel splicing mutation of TMPRSS6 in a Chinese child with iron-refractory iron deficiency anaemia.
A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid.
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine ?-thalassemia intermedia.
Anaemia, iron deficiency and a common polymorphism of iron-regulation, TMPRSS6 rs855791, in Rwandan children.
Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease.
Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation.
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ?-thalassemia intermedia.
Cryptic splice site usage leading to truncated TMPRSS6 is responsible for Iron Refractory Iron Deficiency Anaemia (IRIDA) in an Italian Family.
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of ?-thalassemia.
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
Evaluation of the level of selected iron-related proteins/receptors in the liver of rats during separate/combined vanadium and magnesium administration.
Functional analysis of Matriptase-2 mutations and domains: Insights into the molecular basis of iron refractory iron deficiency anemia.
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Genetic analysis of TMPRSS6 gene in Saudi female patients with iron deficiency anemia.
Genetic variability of TMPRSS6 and its association with iron deficiency anaemia.
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Haematologic data, iron parameters and molecular findings in two new cases of iron-refractory iron deficiency anaemia.
Immunoassay for human serum hemojuvelin.
Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators: a systematic review with meta-analyses.
Iron and hepcidin: a story of recycling and balance.
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Iron deficiency anemia refractory to iron preparations.
Iron disorders of genetic origin: a changing world.
Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
Iron Refractory Iron Deficiency Anaemia: A Rare Cause of Iron Deficiency Anaemia.
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory.
Iron Refractory Iron Deficiency Anemia Due to 374 Base Pairs Deletion in the TMPRSS6 Gene.
Iron Refractory Iron Deficiency Anemia in Dizygotic Twins Due to a Novel TMPRSS6 Gene Mutation in Addition to Polymorphisms Associated With High Susceptibility to Develop Ferropenic Anemia.
Iron refractory iron deficiency anemia.
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Iron-refractory iron deficiency anemia (IRIDA) cases with 2 novel TMPRSS6 mutations.
Iron-refractory iron deficiency anemia (IRIDA).
Iron-refractory iron deficiency anemia: new molecular mechanisms.
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?
Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?
Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
Liver hemojuvelin protein levels in mice deficient in matriptase-2 (Tmprss6).
Liver HFE protein content is posttranscriptionally decreased in iron-deficient mice and rats.
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Matriptase-2: monitoring and inhibiting its proteolytic activity.
Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non-synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemia.
Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).
N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia.
Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia.
Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA).
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia.
Progress in iron metabolism research.
Rapid, accurate detection of TMPRSS6 gene causative mutations with a high-resolution melting assay.
Regulation of TMPRSS6 by BMP6 and iron in human cells and mice.
Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signalling & iron homeostasis.
Responsiveness to oral iron and ascorbic acid in a patient with IRIDA.
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of ?-thalassemia intermedia.
Role of TMPRSS6 rs855791 (T > C) polymorphism in reproductive age women with iron deficiency anemia from Lahore, Pakistan.
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of ?-thalassaemia.
Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals multiple TMPRSS6 gene variations.
The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.
The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia.
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
The role of TMPRSS6/matriptase-2 in iron regulation and anemia.
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
TMPRSS6 rs855791 polymorphism influences the susceptibility to iron deficiency anemia in women at reproductive age.
TMPRSS6 rs855791 Polymorphism Status in Children with Celiac Disease and Anemia.
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child.
Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia (IRIDA).
Very high frequency of TMPRSS6 gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?
[Iron deficiency anaemia due to a matriptase-2 mutation].
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
[Iron metabolism and iron-refractory iron deficiency anemia].
Anemia, Iron-Deficiency
A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype.
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron.
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
A novel mutation Gly603Arg of TMPRSS6 in a Korean female with iron-refractory iron deficiency anemia.
A Novel mutation in the CUB sequence of matriptase-2 (Tmprss6) is implicated in iron-resistant iron deficiency anaemia (IRIDA).
A novel mutation in the CUB sequence of matriptase-2 (TMPRSS6) is implicated in iron-resistant iron deficiency anaemia - response to Jaspers et al.
A novel splice site mutation c.2278 (-1) G>C in the TMPRSS6 gene causes deletion of the substrate binding site of the serine protease resulting in refractory iron deficiency anaemia.
A novel splicing mutation of TMPRSS6 in a Chinese child with iron-refractory iron deficiency anaemia.
A novel tri-allelic mutation of TMPRSS6 in iron-refractory iron deficiency anaemia with response to glucocorticoid.
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
Candidate gene sequencing of SLC11A2 and TMPRSS6 in a family with severe anaemia: common SNPs, rare haplotypes, no causative mutation.
Cryptic splice site usage leading to truncated TMPRSS6 is responsible for Iron Refractory Iron Deficiency Anaemia (IRIDA) in an Italian Family.
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
Functional analysis of Matriptase-2 mutations and domains: Insights into the molecular basis of iron refractory iron deficiency anemia.
Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies.
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Genetic analysis of TMPRSS6 gene in Saudi female patients with iron deficiency anemia.
Genetic variability of TMPRSS6 and its association with iron deficiency anaemia.
Haematologic data, iron parameters and molecular findings in two new cases of iron-refractory iron deficiency anaemia.
Immunoassay for human serum hemojuvelin.
Inactive matriptase-2 mutants found in IRIDA patients still repress hepcidin in a transfection assay despite having lost their serine protease activity.
Into the matrix: regulation of the iron regulatory hormone hepcidin by matriptase-2.
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Iron deficiency anemia refractory to iron preparations.
Iron disorders of genetic origin: a changing world.
Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
Iron Refractory Iron Deficiency Anaemia: A Rare Cause of Iron Deficiency Anaemia.
Iron Refractory Iron Deficiency Anemia (IRIDA): A heterogeneous disease that is not always iron refractory.
Iron Refractory Iron Deficiency Anemia Due to 374 Base Pairs Deletion in the TMPRSS6 Gene.
Iron Refractory Iron Deficiency Anemia in Dizygotic Twins Due to a Novel TMPRSS6 Gene Mutation in Addition to Polymorphisms Associated With High Susceptibility to Develop Ferropenic Anemia.
Iron refractory iron deficiency anemia.
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Iron-deficiency anemia secondary to mutations in genes controlling hepcidin.
Iron-refractory iron deficiency anemia (IRIDA) cases with 2 novel TMPRSS6 mutations.
Iron-refractory iron deficiency anemia (IRIDA).
Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?
Is the acronym IRIDA acceptable for slow responders to iron in the presence of TMPRSS6 mutations?
Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.
Liver hemojuvelin protein levels in mice deficient in matriptase-2 (Tmprss6).
Liver HFE protein content is posttranscriptionally decreased in iron-deficient mice and rats.
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Matriptase-2 (TMPRSS6): a proteolytic regulator of iron homeostasis.
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Matriptase-2: monitoring and inhibiting its proteolytic activity.
Microcytic anaemia with low transferrin saturation, increased serum hepcidin and non-synonymous TMPRSS6 variants: not always iron-refractory iron deficiency anaemia.
Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia.
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA).
N-glycosylation is required for matriptase-2 autoactivation and ectodomain shedding.
Novel missense mutation in the TMPRSS6 gene in a Japanese female with iron-refractory iron deficiency anemia.
Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia.
Novel TMPRSS6 mutations associated with iron-refractory iron deficiency anemia (IRIDA).
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia.
Progress in iron metabolism research.
Rapid, accurate detection of TMPRSS6 gene causative mutations with a high-resolution melting assay.
Regulation of TMPRSS6 by BMP6 and iron in human cells and mice.
Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signalling & iron homeostasis.
Responsiveness to oral iron and ascorbic acid in a patient with IRIDA.
Role of TMPRSS6 rs855791 (T > C) polymorphism in reproductive age women with iron deficiency anemia from Lahore, Pakistan.
Systematic evaluation of paediatric cohort with iron refractory iron deficiency anaemia (IRIDA) phenotype reveals multiple TMPRSS6 gene variations.
The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.
The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia.
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
The role of TMPRSS6/matriptase-2 in iron regulation and anemia.
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
TMPRSS6 rs855791 polymorphism influences the susceptibility to iron deficiency anemia in women at reproductive age.
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Two novel mutations in the tmprss6 gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form.
Two novel mutations in TMPRSS6 associated with iron-refractory iron deficiency anemia in a mother and child.
Two Novel TMPRSS6 Variants in a Compound Heterozygous Child With Iron Refractory Iron Deficiency Anemia (IRIDA).
Very high frequency of TMPRSS6 gene variations in iron deficiency anaemia of patients with polyendocrine autoimmune syndromes: more than a casual association?
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
[Iron metabolism and iron-refractory iron deficiency anemia].
beta-Thalassemia
Iron and hepcidin: a story of recycling and balance.
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Bile Duct Neoplasms
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Breast Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Activated matriptase as a target to treat breast cancer with a drug conjugate.
An investigation of the relationship between TMPRSS6 gene expression, genetic variants and clinical findings in breast cancer.
Coexpression of beta1,6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome.
Critical Adjuvant Influences on Preventive Anti-Metastasis Vaccine Using a Structural Epitope Derived from Membrane Type Protease PRSS14.
Deregulated activation of matriptase in breast cancer cells.
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells.
Diversity of matriptase expression level and function in breast cancer.
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
HAI-1 regulates activation and expression of matriptase, a membrane-bound serine protease.
Hepsin regulates TGF? signaling via fibronectin proteolysis.
Impact of suppression of tumorigenicity 14 (ST14)/serine protease 14 (prss14) expression analysis on the prognosis and management of estrogen receptor negative breast cancer.
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.
N-Glycan Branching Affects the Subcellular Distribution of and Inhibition of Matriptase by HAI-2/Placental Bikunin.
N-terminal processing is essential for release of epithin, a mouse type II membrane serine protease.
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases.
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.
Refinement of the 22q12-q13 Breast Cancer-Associated Region: Evidence of TMPRSS6 as a Candidate Gene in an Eastern Finnish Population.
ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
Strong expression association between matriptase and its substrate prostasin in breast cancer.
Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
The hepatocyte growth factor regulatory factors in human breast cancer.
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.
Type II transmembrane serine protease gene variants associate with breast cancer.
Burkitt Lymphoma
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Carcinogenesis
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Cell Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell Carcinogenesis.
Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase.
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of Matriptase.
Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.
HAI-2 stabilizes, inhibits and regulates SEA-cleavage-dependent secretory transport of matriptase.
Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth.
Hepatocyte growth factor activator inhibitor-1 has a complex subcellular itinerary.
Imaging a functional tumorigenic biomarker in the transformed epithelium.
Insights into the regulation of the matriptase-prostasin proteolytic system.
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.
Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Matriptase: potent proteolysis on the cell surface.
Phenotypic analysis of mice lacking the Tmprss2-encoded protease.
Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-?B signaling and tumor angiogenesis in ApcMin/+ mice.
ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival.
Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The level of claudin-7 is reduced as an early event in colorectal carcinogenesis.
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer.
Carcinoma
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover.
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Deregulated activation of matriptase in breast cancer cells.
Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by down-regulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Differential subcellular localization renders HAI-2 a matriptase inhibitor in breast cancer cells but not in mammary epithelial cells.
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Entosis and apical cell extrusion constitute a tumor-suppressive mechanism downstream of Matriptase.
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells.
Human Cancer Cells Retain Modest Levels of Enzymatically Active Matriptase Only in Extracellular Milieu following Induction of Zymogen Activation.
In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Matriptase activation of Gq drives epithelial disruption and inflammation via RSK and DUOX.
Matriptase activation, an early cellular response to acidosis.
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cells.
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes.
Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis.
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors.
Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.
Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue.
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography.
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Carcinoma, Basal Cell
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Carcinoma, Ductal
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Carcinoma, Endometrioid
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Carcinoma, Hepatocellular
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.
Inflammation regulates TMPRSS6 expression via STAT5.
Carcinoma, Intraductal, Noninfiltrating
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Carcinoma, Ovarian Epithelial
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Carcinoma, Papillary
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Carcinoma, Renal Cell
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Carcinoma, Squamous Cell
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
DESC1, a novel tumor suppressor, sensitizes cells to apoptosis by down-regulating the EGFR/AKT pathway in esophageal squamous cell carcinoma.
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes.
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Carcinoma, Transitional Cell
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Celiac Disease
About TMPRSS6 rs855791 polymorphism, iron metabolism and celiac disease.
The role of TMPRSS6 and HFE variants in iron deficiency anemia in celiac disease.
TMPRSS6 rs855791 Polymorphism Status in Children with Celiac Disease and Anemia.
Colitis
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis.
Colitis, Ulcerative
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Colonic Neoplasms
Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors.
Imaging a functional tumorigenic biomarker in the transformed epithelium.
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells.
Colorectal Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
The ratio of Matriptase/HAI-1 mRNA is higher in colorectal cancer adenomas and carcinomas than corresponding tissue from control individuals.
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
Common Cold
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Coronavirus Infections
Biochemical Characterization of Middle East Respiratory Syndrome Coronavirus Spike Protein Proteolytic Processing.
TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection.
COVID-19
ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.
Characteristics of Angiotensin I-converting enzyme 2, type II transmembrane serine protease 2 and 4 in tree shrew indicate it as a potential animal model for SARS-CoV-2 infection.
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019.
Crohn Disease
Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis.
Matriptase protects against experimental colitis and promotes intestinal barrier recovery.
Cystic Fibrosis
Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells.
Deafness
Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss.
Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing.
TMPRSS3, a type II transmembrane serine protease mutated in non-syndromic autosomal recessive deafness.
Dehydration
Activity and inhibition of prostasin and matriptase on apical and basolateral surfaces of human airway epithelial cells.
Diabetes Mellitus, Type 2
A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants.
Association of TMPRSS6 polymorphisms with ferritin, hemoglobin, and type 2 diabetes risk in a Chinese Han population.
Diabetes, Gestational
Associations of TMPRSS6 Polymorphisms with Gestational Diabetes Mellitus in Chinese Han Pregnant Women: a Preliminary Cohort Study.
Dysgerminoma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Endodermal Sinus Tumor
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Endometrial Hyperplasia
Expression of matriptase and clinical outcome of human endometrial cancer.
Endometrial Neoplasms
Expression of matriptase and clinical outcome of human endometrial cancer.
Regulation of matriptase and HAI-1 system, a novel therapeutic target in human endometrial cancer cells.
Esophageal Squamous Cell Carcinoma
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Fibroadenoma
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Fibroma
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Fibrosarcoma
Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk.
Gastritis, Atrophic
Iron deficiency anemia refractory to iron preparations.
Genetic Diseases, Inborn
Matriptase Expression and Zymogen Activation in Human Pilosebaceous Unit.
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
The spatiotemporal control of human matriptase action on its physiological substrates: a case against a direct role for matriptase proteolytic activity in profilaggrin processing and desquamation.
[Iron metabolism and iron-refractory iron deficiency anemia].
Glioma
Aberrations in the Iron Regulatory Gene Signature Are Associated with Decreased Survival in Diffuse Infiltrating Gliomas.
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Proteolytic cleavage of human acid-sensing ion channel 1 by the serine protease matriptase.
Granulosa Cell Tumor
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Hearing Loss
Defective Tmprss3-Associated Hair Cell Degeneration in Inner Ear Organoids.
Mice deficient for the type II transmembrane serine protease, TMPRSS1/hepsin, exhibit profound hearing loss.
Thyroxine treatments do not correct inner ear defects in tmprss1 mutant mice.
Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing.
Hemochromatosis
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis.
Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study.
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Iron and hepcidin: a story of recycling and balance.
Iron regulation by hepcidin.
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Progress in iron metabolism research.
Reducing TMPRSS6 ameliorates hemochromatosis and ?-thalassemia in mice.
SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
Hemophilia A
[Detection of the heterozygote carrier state and prenatal diagnosis of hemophilia A using DNA probes]
Hepatitis C, Chronic
Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients.
Hyperferritinemia
Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.
Hypersensitivity
[Association of FokI rs2228570 and TMPRSS6 rs855791 polymorphisms with cow's milk protein allergy in children].
Hypohidrosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Hypotrichosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.
Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype.
Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing.
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
The matriptase-prostasin proteolytic cascade in epithelial development and pathology.
Ichthyosis
A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome.
Autosomal ichthyosis with hypotrichosis syndrome displays low matriptase proteolytic activity and is phenocopied in ST14 hypomorphic mice.
Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase.
Autosomal recessive ichthyosis with hypotrichosis syndrome: further delineation of the phenotype.
Genetic skin diseases related to desmosomes and corneodesmosomes.
Ichthyosis, Follicular Atrophoderma, and Hypotrichosis Caused by Mutations in ST14 Is Associated with Impaired Profilaggrin Processing.
Loss of Matriptase Suppression Underlies Spint1 Mutation-Associated Ichthyosis and Postnatal Lethality.
Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins.
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Mutation G827R in Matriptase Causing Autosomal Recessive Ichthyosis with Hypotrichosis Yields an Inactive Protease.
Idiopathic Pulmonary Fibrosis
Matriptase, Protease-activated Receptor 2, and Idiopathic Pulmonary Fibrosis. Further Evidence for Signaling Pathway Redundancy in this Difficult-to-Treat Disease?
Infections
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression.
Hepcidin in Iron Homeostasis: Diagnostic and Therapeutic Implications in Type 2 Diabetes Mellitus Patients.
Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteolysis and signaling.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection Mediated by the Transmembrane Serine Protease TMPRSS2.
The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.
Inflammatory Breast Neoplasms
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Influenza, Human
Cleavage Activation of the Human-Adapted Influenza Virus Subtypes by Matriptase Reveals both Subtype and Strain Specificities.
DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry.
Evidence that TMPRSS2 activates the SARS-coronavirus spike-protein for membrane fusion and reduces viral control by the humoral immune response.
Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation.
Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium.
Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses.
Non-human primate orthologues of TMPRSS2 cleave and activate the influenza virus hemagglutinin.
SPINT2 inhibits proteases involved in activation of both influenza viruses and metapneumoviruses.
Insulin Resistance
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
Insulinoma
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Intestinal Failure
Matriptase drives early-onset intestinal failure in a mouse model of congenital tufting enteropathy.
Iron Deficiencies
Anaemia, iron deficiency and a common polymorphism of iron-regulation, TMPRSS6 rs855791, in Rwandan children.
Common TMPRSS6 mutations and iron, erythrocyte, and pica phenotypes in 48 women with iron deficiency or depletion.
Does TMPRSS6 RS855791 polymorphism contribute to iron deficiency in treated celiac disease?
Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats.
Fine tuning of hepcidin expression by positive and negative regulators.
Heeney MM, Guo D, De Falco L, et al. Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency. Blood. 2018;132(4):448-452.
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Iron homeostasis and nutritional iron deficiency.
Iron Refractory Iron Deficiency Anaemia: A Rare Cause of Iron Deficiency Anaemia.
Iron refractory iron deficiency anemia.
Iron-refractory iron deficiency anemia.
Iron-refractory iron deficiency anemia: new molecular mechanisms.
Low intracellular iron increases the stability of matriptase-2.
Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis.
Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms.
Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model.
Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency.
Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia.
Severe microcytic anemia but increased erythropoiesis in mice lacking Hfe or Tfr2 and Tmprss6.
Study the association of transmembrane serine protease 6 gene polymorphisms with iron deficiency status in Saudi Arabia.
Suppression of the hepcidin-encoding gene Hamp permits iron overload in mice lacking both hemojuvelin and matriptase-2/TMPRSS6.
The erythroid function of Transferrin Receptor 2 revealed by Tmprss6inactivation in different models of Transferrin Receptor 2 knock out mice.
The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin.
The serine protease TMPRSS6 is required to sense iron deficiency.
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.
Transferrin Receptor 1 Regulates Thermogenic Capacity and Cell Fate in Brown/Beige Adipocytes.
Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency.
Iron Metabolism Disorders
A child with severe iron-deficiency anemia and a complex TMPRSS6 genotype.
A novel homozygous nonsense mutation (p.Y78*) in TMPRSS6 gene causing iron-refractory iron deficiency anemia (IRIDA) in two siblings.
Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines.
Iron Overload
3,1-Benzothiazines, 1,4-Benzodioxines and 1,4-Benzoxazines as Inhibitors of Matriptase-2: Outcome of a Focused Screening Approach.
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
A strong anti-inflammatory signature revealed by liver transcription profiling of Tmprss6-/- mice.
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine ?-thalassemia intermedia.
Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ?-thalassemia intermedia.
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of ?-thalassemia.
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis.
Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats.
En Route to New Therapeutic Options for Iron Overload Diseases: Matriptase-2 as a Target for Kunitz-Type Inhibitors.
Evaluation of bisbenzamidines as inhibitors for matriptase-2.
Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
Hepatocyte growth factor activator inhibitor type 2 (HAI-2) modulates hepcidin expression by inhibiting the cell surface protease matriptase-2.
Identification of the first low-molecular-weight inhibitors of matriptase-2.
Iron deficiency anemia due to matriptase-2 inactivation is dependent upon the presence of functional Bmp6.
Matriptase-2: monitoring and inhibiting its proteolytic activity.
Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids.
Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of ?-thalassemia intermedia.
SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of ?-thalassaemia.
Striking the target in iron overload disorders.
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice.
[Iron deficiency and overload. Implications in oxidative stress and cardiovascular health]
Kidney Diseases
Proteolytic Cleavage of Podocin by Matriptase Exacerbates Podocyte Injury.
Kidney Failure, Chronic
Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease.
Leukemia
A novel serine protease SNC19 associated with human colorectal cancer.
Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains.
Leukemia, Lymphocytic, Chronic, B-Cell
Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion.
Leukemia, Myeloid, Acute
[Expression and Clinical Significances of HGFA, Matriptase, HAI-1 and HAI-2 in Acute Myeloid Leukemia].
[Expression level and Clinical Significance of Serum SE-CAD and Matriptase in Patients with Acute Myeloid Leukemia].
Liver Cirrhosis
Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis.
Liver Diseases
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Lung Injury
Membrane-anchored Serine Protease Matriptase is a Trigger of Pulmonary Fibrogenesis.
Lung Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Lymphatic Metastasis
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Expression of matriptase and clinical outcome of human endometrial cancer.
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Lymphoma
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.
A novel serine protease SNC19 associated with human colorectal cancer.
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Lymphoma, B-Cell
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Lymphoma, Follicular
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Lymphoma, Mantle-Cell
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.
matriptase deficiency
Decreased hemojuvelin protein levels in mask mice lacking matriptase-2-dependent proteolytic activity.
EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency.
Iron disorders of genetic origin: a changing world.
Iron refractory iron deficiency anemia.
Matriptase Regulates Proliferation and Early, but Not Terminal, Differentiation of Human Keratinocytes.
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
The spatiotemporal control of human matriptase action on its physiological substrates: a case against a direct role for matriptase proteolytic activity in profilaggrin processing and desquamation.
[Iron deficiency anaemia due to a matriptase-2 mutation].
Melanoma
A novel serine protease SNC19 associated with human colorectal cancer.
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
Mesothelioma, Malignant
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma.
Milk Hypersensitivity
[Association of FokI rs2228570 and TMPRSS6 rs855791 polymorphisms with cow's milk protein allergy in children].
Neoplasm Metastasis
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
Decreasing the ratio of matriptase/HAI?1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Differential expression of genes encoding proteins of the HGF/MET system in insulinomas.
Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors.
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation.
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance.
Expression of matriptase and clinical outcome of human endometrial cancer.
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Intramembrane proteolysis of an extracellular serine protease, epithin/PRSS14, enables its intracellular nuclear function.
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell carcinoma: immunohistochemical analysis.
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Shedding of epithin/PRSS14 is induced by TGF-? and mediated by tumor necrosis factor-? converting enzyme.
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans.
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
[Study on post-translational processing and active forms of the novel metastasis-associated protein SNC19]
Neoplasms
3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.
?-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
A nanometer-sized protease inhibitor for precise cancer diagnosis and treatment.
A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
A novel serine protease SNC19 associated with human colorectal cancer.
A pan-cancer analysis of alternative splicing events reveals novel tumor-associated splice variants of matriptase.
A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase.
Activated matriptase as a target to treat breast cancer with a drug conjugate.
Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Addition of beta1-6 GlcNAc branching to the oligosaccharide attached to Asn 772 in the serine protease domain of matriptase plays a pivotal role in its stability and resistance against trypsin.
An investigation of the relationship between TMPRSS6 gene expression, genetic variants and clinical findings in breast cancer.
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Bikunin target genes in ovarian cancer cells identified by microarray analysis.
c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase.
Cell Surface Human Airway Trypsin-Like Protease Is Lost During Squamous Cell Carcinogenesis.
Characterization of matriptase expression in normal human tissues.
Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Co-localization of the channel activating protease prostasin/(CAP1/PRSS8) with its candidate activator, matriptase.
Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1.
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway.
Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Decreased matriptase/HAI-1 ratio in advanced colorectal adenocarcinoma of Chinese patients.
Deregulated activation of matriptase in breast cancer cells.
Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.
Design and synthesis of potent, selective inhibitors of matriptase.
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Differential Tumorigenic Potential and Matriptase Activation between PDGF B versus PDGF D in Prostate Cancer.
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Diversity of matriptase expression level and function in breast cancer.
Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma.
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.
Epithin, a target of transforming growth factor-beta signaling, mediates epithelial-mesenchymal transition.
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Expression and prognostic value of matriptase in ovarian serous adenocarcinoma.
Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters.
Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: Clinical and biological significance.
Expression of matriptase and clinical outcome of human endometrial cancer.
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters.
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers.
Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Gold nanoparticles based molecular beacons for in vitro and in vivo detection of the matriptase expression on tumor.
HAI-2 stabilizes, inhibits and regulates SEA-cleavage-dependent secretory transport of matriptase.
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
HATL5: A Cell Surface Serine Protease Differentially Expressed in Epithelial Cancers.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
High expression level of TMPRSS4 predicts adverse outcomes of colorectal cancer patients.
High-affinity cyclic peptide matriptase inhibitors.
Human Cancer Cells Retain Modest Levels of Enzymatically Active Matriptase Only in Extracellular Milieu following Induction of Zymogen Activation.
Imaging a functional tumorigenic biomarker in the transformed epithelium.
Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.
Imbalanced matriptase pericellular proteolysis contributes to the pathogenesis of malignant B-cell lymphomas.
Improving the species cross-reactivity of an antibody using computational design.
Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia.
Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Inhibition of an active zymogen protease: the zymogen form of matriptase is regulated by HAI-1 and HAI-2.
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Inhibition of human matriptase by eglin c variants.
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Intramembrane proteolysis of an extracellular serine protease, epithin/PRSS14, enables its intracellular nuclear function.
Kallikrein 5 Inhibition by the Lympho-Epithelial Kazal-Type Related Inhibitor Hinders Matriptase-Dependent Carcinogenesis.
Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer.
Knockdown of TMPRSS3, a Transmembrane Serine Protease, Inhibits the Proliferation, Migration, and Invasion in Human Nasopharyngeal Carcinoma Cells.
Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Matriptase activation connects tissue factor-dependent coagulation initiation to epithelial proteolysis and signaling.
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Matriptase and its putative role in cancer.
Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
Matriptase expression in the normal and neoplastic mast cells.
Matriptase is highly upregulated in chronic lymphocytic leukemia and promotes cancer cell invasion.
Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion.
Matriptase promotes inflammatory cell accumulation and progression of established epidermal tumors.
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer.
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients.
Matriptase-2 inhibits HECV motility and tubule formation in vitro and tumour angiogenesis in vivo.
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
Matriptase: a culprit in cancer?
Matriptase: potent proteolysis on the cell surface.
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1.
Mechanisms of hepatocyte growth factor activation in cancer tissues.
Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase.
MT-SP1 proteolysis and regulation of cell-microenvironment interactions.
Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention.
Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma.
Overexpression of matriptase in tumor stroma is a poor prognostic indicator of extrahepatic bile duct cancer.
Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Polyserase-1/TMPRSS9 induces pro-tumor effects in pancreatic cancer cells by activation of pro-uPA.
Potent and specific inhibition of the biological activity of the type-II transmembrane serine protease matriptase by the cyclic microprotein MCoTI-II.
Probing the interaction mechanism of small molecule inhibitors with matriptase based on molecular dynamics simulation and free energy calculations.
Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin.
Prognostic value of TMPRSS4 expression in patients with breast cancer.
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Protease-activated receptor-2 accelerates intestinal tumor formation through activation of nuclear factor-?B signaling and tumor angiogenesis in ApcMin/+ mice.
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
PRSS14/Epithin is induced in macrophages by the IFN-?/JAK/STAT pathway and mediates transendothelial migration.
Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy.
Role of TMPRSS4 Modulation in Breast Cancer Cell Proliferation.
Sampling the N-terminal proteome of human blood.
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Shedding of epithin/PRSS14 is induced by TGF-? and mediated by tumor necrosis factor-? converting enzyme.
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities.
Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors.
SPINT2 Deregulation in Prostate Carcinoma.
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.
Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.
Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling.
The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma.
THE IMPACT OF ALCOHOL ON PRO-METASTATIC N-GLYCOSYLATION IN PROSTATE CANCER.
The influence of matriptase-2 on prostate cancer in vitro: A possible role for ?-catenin.
The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma.
The role of TMPRSS6/matriptase-2 in iron regulation and anemia.
The type II transmembrane serine protease matriptase-2--identification, structural features, enzymology, expression pattern and potential roles.
The type II transmembrane serine protease, matriptase-2: Possible links to cancer?
Time-domain in vivo near infrared fluorescence imaging for evaluation of matriptase as a potential target for the development of novel, inhibitor-based tumor therapies.
TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer.
TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019.
TMPRSS4 correlates with colorectal cancer pathological stage and regulates cell proliferation and self-renewal ability.
TMPRSS4 induces cancer cell invasion through pro-uPA processing.
TMPRSS4 induces cancer stem cell-like properties in lung cancer cells and correlates with ALDH expression in NSCLC patients.
TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways.
TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1.
TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections.
TMPRSS4 upregulates uPA gene expression through JNK signaling activation to induce cancer cell invasion.
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
Tumor detection by imaging proteolytic activity.
Type II transmembrane serine protease (TTSP) deregulation in cancer.
Type II transmembrane serine proteases as potential targets for cancer therapy.
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Zebrafish modeling reveals that SPINT1 regulates the aggressiveness of skin cutaneous melanoma and its crosstalk with tumor immune microenvironment.
[Study on post-translational processing and active forms of the novel metastasis-associated protein SNC19]
Netherton Syndrome
Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Neural Tube Defects
Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice.
Neuroblastoma
Matriptase cleaves the amyloid-beta peptide 1-42 at Arg-5, Lys-16, and Lys-28.
Non-alcoholic Fatty Liver Disease
The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease.
Obesity
Matriptase-2 deficiency protects from obesity by modulating iron homeostasis.
Osteoarthritis
Changing the selectivity profile - from substrate analog inhibitors of thrombin and factor Xa to potent matriptase inhibitors.
Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.
Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms.
Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis.
Protease activated receptor 2 and matriptase expression in the joints of cats with and without osteoarthritis.
Ovarian Neoplasms
Decreasing the ratio of matriptase/HAI?1 by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.
Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Increasing expression of serine protease matriptase in ovarian tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters.
Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
Possible role of matriptase in the diagnosis of ovarian cancer.
Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.
[Expression and significance of matriptase in ovarian cancer cells with diverse metastatic potential].
Pancreatic Neoplasms
Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Examination of HFE associations with childhood leukemia risk and extension to other iron regulatory genes.
Prostatic Hyperplasia
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Prostatic Intraepithelial Neoplasia
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Prostatic Neoplasms
A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis.
Author Correction: The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
Curcumin-targeting Pericellular Serine Protease Matriptase Role in Suppression of Prostate Cancer Cell Invasion, Tumor Growth and Metastasis.
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Development of an Activatable Fluorescent Probe for Prostate Cancer Imaging.
Differential Tumorigenic Potential and Matriptase Activation between PDGF B versus PDGF D in Prostate Cancer.
Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach.
Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Dynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.
Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
From in-silico to Experimental Validation: Tailoring Peptide Substrates for a Serine Protease.
Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase.
Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Hepsin inhibits CDK11p58 IRES activity by suppressing unr expression and eIF-2? phosphorylation in prostate cancer.
HEPSIN inhibits cell growth/invasion in prostate cancer cells.
HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer Immunotherapy.
Identification and characterization of small-molecule inhibitors of hepsin.
Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.
Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells.
Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
Matriptase Is Involved in ErbB-2-Induced Prostate Cancer Cell Invasion.
Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.
Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors.
Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors.
The influence of matriptase-2 on prostate cancer in vitro: A possible role for ?-catenin.
The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.
TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer.
Pulmonary Fibrosis
Membrane-anchored Serine Protease Matriptase is a Trigger of Pulmonary Fibrogenesis.
Renal Insufficiency, Chronic
TMPRSS6 rs855791 polymorphism and susceptibility to iron deficiency anaemia in non-dialysis chronic kidney disease patients in South Africa.
Restless Legs Syndrome
Genetic factors influencing hemoglobin levels in 15,567 blood donors: results from the Danish Blood Donor Study.
Sarcoma
Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo.
Severe Acute Respiratory Syndrome
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
Sex, Hormones, Immune Functions, and Susceptibility to Coronavirus Disease 2019 (COVID-19)-Related Morbidity.
Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
Skin Diseases
Increased matriptase zymogen activation in inflammatory skin disorders.
Toward the first class of suicide inhibitors of kallikreins involved in skin diseases.
Skin Neoplasms
Role of Matriptase and Proteinase-Activated Receptor-2 in Nonmelanoma Skin Cancer.
Squamous Cell Carcinoma of Head and Neck
Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2.
Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma.
Stomach Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching.
TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition.
Thalassemia
Design and chemical syntheses of potent matriptase-2 inhibitors based on trypsin inhibitor SFTI-1 isolated from sunflower seeds.
Iron and hepcidin: a story of recycling and balance.
The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment.
The V736A TMPRSS6 polymorphism influences liver iron concentration in nontransfusion-dependent thalassemias.
Thrombocytosis
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Humans and Mice.
Thromboembolism
Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Thymoma
Epithin/PRSS14 proteolytically regulates angiopoietin receptor Tie2 during transendothelial migration.
Soluble epithin/PRSS14 secreted from cancer cells contains active angiogenic potential.
Thyroid Neoplasms
Co-expression of matriptase and N-acetylglucosaminyltransferase V in thyroid cancer tissues--its possible role in prolonged stability in vivo by aberrant glycosylation.
Triple Negative Breast Neoplasms
Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer.
Urinary Bladder Neoplasms
Expression of protease activating receptor-2 (PAR-2) is positively correlated with the recurrence of non-muscle invasive bladder cancer: an immunohistochemical analysis.
Ibuprofen regulates the expression and function of membrane-associated serine proteases prostasin and matriptase.
Matriptase-Induced Phosphorylation of MET is Significantly Associated with Poor Prognosis in Invasive Bladder Cancer; an Immunohistochemical Analysis.
Urologic Neoplasms
Dysregulation of Type II Transmembrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers.
Uterine Cervical Neoplasms
A novel serine protease SNC19 associated with human colorectal cancer.
Virus Diseases
TMPRSS4 is a type II transmembrane serine protease involved in cancer and viral infections.